Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ELVN
ELVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ELVN News
Enliven Therapeutics Executive Sells 20,000 Shares
Feb 01 2026
Fool
Enliven Therapeutics COO Anish Patel Sells 48,300 Shares for $1,351,000
Jan 13 2026
Yahoo Finance
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Enliven Therapeutics Reports Promising Phase 1b Data for ELVN-001 in CML Patients
Jan 08 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
Jan 08 2026
Benzinga
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
Jan 08 2026
Benzinga
Enliven Therapeutics ELVN-001 Achieves 69% MMR at 24 Weeks in Phase 1b Trial
Jan 08 2026
Newsfilter
Enliven Appoints Scott Garland to Board, Focuses on ELVN-001 Commercialization
Jan 07 2026
PRnewswire
Enliven Appoints Scott Garland to Board, Focuses on ELVN-001 Commercialization
Jan 07 2026
Newsfilter
Enliven Grants CEO Richard Fair 875,000 Stock Options at $18.77 Each
Dec 11 2025
PRnewswire
ELVN Experiences Significant Drop Below Key Moving Average
Dec 09 2025
NASDAQ.COM
Small Biotech Terns Targets Novartis' Leading Leukemia Drug
Dec 09 2025
Benzinga
ELVN Surpasses Important Moving Average Threshold
Nov 12 2025
NASDAQ.COM
Show More News
